Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AJU-C52L vs Co-administration in Healthy Adults
NCT05077475Phase 1Unknown
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amlodipine + chlorthalidone + valsartan in hypertension (HTN) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Area Under the Concentration-time Curve to the Last Measurable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.
02
Drugs
amlodipine + chlorthalidone + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05077475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077475.